Literature DB >> 16582626

p14ARF triggers G2 arrest through ERK-mediated Cdc25C phosphorylation, ubiquitination and proteasomal degradation.

Beatrice Eymin1, Paule Claverie, Caroline Salon, Christian Brambilla, Elisabeth Brambilla, Sylvie Gazzeri.   

Abstract

The Cdc25C phosphatase is a key regulator of mitotic entry which activity is tightly regulated by phosphorylation. In response to DNA damage, phosphorylation at serine 216 induces the cytosolic retention of Cdc25C through 14-3-3 binding. We previously reported the ability of the p14ARF tumor suppressor to induce the accumulation of inactive phospho-Cdc25C(Ser216) protein as well as a decrease of Cdc25C steady state level and correlated these events with a p53-independent G2 arrest. The aim of this study was to investigate the cellular signaling pathways involved in this process. By using specific pharmacological inhibitors, we demonstrate that activation of the ERK1/2 MAP kinases pathway is involved in the p53-independent G2 checkpoint induced by p14ARF Moreover, we show that activated P-ERK1/2 bind and phosphorylate Cdc25C on its ser216 residue following p14ARF expression, thereby identifying Cdc25C as a new ERK1/2 target. Importantly, we further show that phosphorylation at Ser216 by phospho-ERK1/2 promotes Cdc25C ubiquitination and proteasomal degradation, suggesting that Cdc25C proteolysis is required for a sustained G2 arrest in response to p14ARF. Taken together, these results demonstrate that the MAPK ERK signaling pathway contributes to the p53-independent antiproliferative functions of p14ARF. Furthermore, they identify a new mechanism by which phosphorylation at serine 216 participates to Cdc25C inactivation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16582626     DOI: 10.4161/cc.5.7.2625

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  16 in total

1.  Systematic genetic dissection of p14ARF-mediated mitochondrial cell death signaling reveals a key role for p21CDKN1 and the BH3-only protein Puma/bbc3.

Authors:  Philipp G Hemmati; Annika Müer; Bernd Gillissen; Tim Overkamp; Ana Milojkovic; Jana Wendt; Bernd Dörken; Peter T Daniel
Journal:  J Mol Med (Berl)       Date:  2010-04-25       Impact factor: 4.599

2.  Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors.

Authors:  Yong Tang; Hossein A Hamed; Andrew Poklepovic; Yun Dai; Steven Grant; Paul Dent
Journal:  Mol Pharmacol       Date:  2012-05-17       Impact factor: 4.436

3.  Mdm2 promotes Cdc25C protein degradation and delays cell cycle progression through the G2/M phase.

Authors:  L E Giono; L Resnick-Silverman; L A Carvajal; S St Clair; J J Manfredi
Journal:  Oncogene       Date:  2017-08-14       Impact factor: 9.867

4.  ARF triggers cell G1 arrest by a P53 independent ERK pathway.

Authors:  Hansong Du; Weiqi Yao; Min Fang; Dongcheng Wu
Journal:  Mol Cell Biochem       Date:  2011-06-10       Impact factor: 3.396

5.  Association and clinicopathologic significance of p38MAPK-ERK-JNK-CDC25C with polyploid giant cancer cell formation.

Authors:  Kai Liu; Rui Lu; Qi Zhao; Jiaxing Du; Yuwei Li; Minying Zheng; Shiwu Zhang
Journal:  Med Oncol       Date:  2019-11-16       Impact factor: 3.064

6.  Significance of MDM2 and P14 ARF polymorphisms in susceptibility to differentiated thyroid carcinoma.

Authors:  Fenghua Zhang; Li Xu; Qingyi Wei; Xicheng Song; Erich M Sturgis; Guojun Li
Journal:  Surgery       Date:  2012-12-04       Impact factor: 3.982

7.  MAPK pathway activation delays G2/M progression by destabilizing Cdc25B.

Authors:  Puji Astuti; Tanya Pike; Charlotte Widberg; Elizabeth Payne; Angus Harding; John Hancock; Brian Gabrielli
Journal:  J Biol Chem       Date:  2009-10-01       Impact factor: 5.157

Review 8.  Pectenotoxin-2 from marine sponges: a potential anti-cancer agent-a review.

Authors:  Gi-Young Kim; Wun-Jae Kim; Yung Hyun Choi
Journal:  Mar Drugs       Date:  2011-11-02       Impact factor: 6.085

9.  Androgens upregulate Cdc25C protein by inhibiting its proteasomal and lysosomal degradation pathways.

Authors:  Yu-Wei Chou; Li Zhang; Sakthivel Muniyan; Humera Ahmad; Satyendra Kumar; Syed Mahfuzul Alam; Ming-Fong Lin
Journal:  PLoS One       Date:  2013-04-18       Impact factor: 3.240

10.  Therapeutic targeting of cancer cell cycle using proteasome inhibitors.

Authors:  Namrata Rastogi; Durga Prasad Mishra
Journal:  Cell Div       Date:  2012-12-26       Impact factor: 5.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.